NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (vol 391, pg 1174, 2018)

被引：0
|
作者：
Harrison, S. A.
Rinella, M. E.
Abdelmalek, M. F.
机构：
来源：
LANCET | 2018年 / 391卷 / 10126期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E16 / E16
页数：1
相关论文
共 50 条
  • [11] Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran
    Baniasadi, Nadieh
    Salajegheh, Faranak
    Pardakhty, Abbas
    Seyedmirzaee, Seyed Mehdi
    Hayatbakhsh, Mohammad Mahdi
    Nikpoor, Amin Reza
    Mohammadi, Mojgan
    HEPATITIS MONTHLY, 2015, 15 (11)
  • [12] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
    Younossi, Zobair M.
    Ratziu, Vlad
    Loomba, Rohit
    Rinella, Mary
    Anstee, Quentin M.
    Goodman, Zachary
    Bedossa, Pierre
    Geier, Andreas
    Beckebaum, Susanne
    Newsome, Philip N.
    Sheridan, David
    Sheikh, Muhammad Y.
    Trotter, James
    Knapple, Whitfield
    Lawitz, Eric
    Abdelmalek, Manal F.
    Kowdley, Kris V.
    Montano-Loza, Aldo J.
    Boursier, Jerome
    Mathurin, Philippe
    Bugianesi, Elisabetta
    Mazzella, Giuseppe
    Olveira, Antonio
    Cortez-Pinto, Helena
    Graupera, Isabel
    Orr, David
    Gluud, Lise Lotte
    Dufour, Jean-Francois
    Shapiro, David
    Campagna, Jason
    Zaru, Luna
    MacConell, Leigh
    Shringarpure, Reshma
    Harrison, Stephen
    Sanyal, Arun J.
    LANCET, 2019, 394 (10215): : 2184 - 2196
  • [13] FINAL ANALYSIS OF A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ALDAFERMIN (NGM282) IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
    Harrison, Stephen A.
    Neff, Guy
    Guy, Cynthia D.
    Bashir, Mustafa
    Paredes, Angelo
    Pablo Fries, Juan
    Younes, Ziad H.
    Trotter, James F.
    Gunn, Nadege T.
    Moussa, Sam
    Kohli, Anita
    Nelson, Kristin
    Gottwald, Mildred
    Chang, William
    Yan, Andrew Z.
    DePaoli, Alex
    Ling, Lei
    Lieu, Hsiao
    HEPATOLOGY, 2020, 72 : 55A - 56A
  • [14] LIPID MANAGEMENT IN A 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALDAFERMIN (NGM282)
    Gunn, Nadege T.
    Ling, Lei
    Neff, Guy
    Guy, Cynthia D.
    Bashir, Mustafa
    Frias, Juan Pablo
    Younes, Ziad H.
    Trotter, James F.
    Moussa, Sam
    Kohli, Anita
    Connelly, Margery A.
    Nelson, Kristin
    Gottwald, Mildred
    Chang, William
    Yan, Andrew Z.
    DePaoli, Alex
    Lieu, Hsiao
    Harrison, Stephen A.
    HEPATOLOGY, 2020, 72 : 1022 - 1023
  • [15] Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
    Kessoku, Takaomi
    Imajo, Kento
    Kobayashi, Takashi
    Ozaki, Anna
    Iwaki, Michihiro
    Honda, Yasushi
    Kato, Takayuki
    Ogawa, Yuji
    Tomeno, Wataru
    Kato, Shingo
    Higurashi, Takuma
    Yoneda, Masato
    Kirikoshi, Hiroyuki
    Kubota, Kazumi
    Taguri, Masataka
    Yamanaka, Takeharu
    Usuda, Haruki
    Wada, Koichiro
    Kobayashi, Noritoshi
    Saito, Satoru
    Nakajima, Atsushi
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (11): : 996 - 1007
  • [16] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (vol 394, pg 2184, 2019)
    Younossi, Z. M.
    Ratziu, V
    Loomba, R.
    LANCET, 2020, 396 (10247): : 312 - 312
  • [17] LIRAGLUTIDE IS EFFECTIVE IN THE HISTOLOGICAL CLEARANCE OF NON-ALCOHOLIC STEATOHEPATITIS IN A MULTICENTRE, DOUBLE-BLINDED, RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL
    Armstrong, M. J.
    Gaunt, P.
    Aithal, G. P.
    Parker, R.
    Barton, D.
    Hull, D.
    Guo, K.
    Abouda, G.
    Aldersley, M.
    Gough, S. C.
    Tomlinson, J. W.
    Brown, R. M.
    Ubscher, S. G. H.
    Newsome, P. N.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S187 - S187
  • [18] LIRAGLUTIDE IS EFFECTIVE IN THE HISTOLOGICAL CLEARANCE OF NON-ALCOHOLIC STEATOHEPATITIS IN A MULTICENTRE, DOUBLE-BLINDED, RANDOMISED, PLACEBO-CONTROLLED PHASE II TRIAL
    Armstrong, M. J.
    Gaunt, P.
    Aithal, G. P.
    Parker, R.
    Barton, D.
    Hall, D.
    Guo, K.
    Abouda, G.
    Aldersley, M.
    Gough, S. C.
    Tomlinson, J. W.
    Brown, R.
    Hubscher, S. G.
    Newsome, P. N.
    GUT, 2015, 64 : A9 - A9
  • [19] NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double Blind Placebo Controlled Trial
    Mayo, Marlyn J.
    Wigg, Alan J.
    Leggett, Barbara A.
    Arnold, Hays
    Thompson, Alexander J.
    Weltman, Martin
    Carey, Elizabeth J.
    Muir, Andrew J.
    Ling, Lei
    Rossi, Stephen J.
    Depaoli, Alex M.
    HEPATOLOGY COMMUNICATIONS, 2018, 2 (09) : 1037 - 1050
  • [20] Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
    Hirschfield, Gideon M.
    Chazouilleres, Olivier
    Drenth, Joost P.
    Thorburn, Douglas
    Harrison, Stephen A.
    Landis, Charles S.
    Mayo, Marlyn J.
    Muir, Andrew J.
    Trotter, James F.
    Leeming, Diana J.
    Karsdal, Morten A.
    Jaros, Mark J.
    Ling, Lei
    Kim, Kathline H.
    Rossi, Stephen J.
    Somaratne, Ransi M.
    DePaoli, Alex M.
    Beuers, Ulrich
    JOURNAL OF HEPATOLOGY, 2019, 70 (03) : 483 - 493
12345